Literature DB >> 31763222

Does Separate Administration of Montelukast and Levocetirizine Provide Better Results in Perennial Allergic Rhinitis: A Hospital Based Study.

Sumit Chattopadhyay1, Aloke Bose Majumdar1, Arup Sengupta1, Dipayan Biswas1, Ayon Pal2, Nilanjan Dastidar3.   

Abstract

To determine whether separate administration of Montelukast and Levocetirizine provide a better response in perennial allergic rhinitis (PAR) than their fixed dose combination. Total 151 patients underwent a hospital based clinical study, being divided in 3 discrete groups. One group was given non-bilayered combination of Montelukast and Levocetrizine, 2nd group was given their bilayered counterpart whereas 3rd group was given the drugs at 12 h interval. Medications were continued for 3 months before stoppage. All patients were followed up for 1 month more to note recurrence of symptoms of PAR on weekly basis. While the combination formulation gave 9.8 and 12.6 % symptom-free patients; separate administration of the molecules gave 43.3 % positive (symptom-free 1 month) result. Fixed-dose combination is found to cause 1.4 times more chance of recurrence. Though per se, Montelukast and Levocetrizine does not give excellent response in PAR, their separate administration provides better outcome. So a morning dose of Montelukast and Levocetirizine at bed time is recommended while treating PAR. © Association of Otolaryngologists of India 2015.

Entities:  

Keywords:  Levocetirizine; Montelukast; PAR; Perennial allergic rhinitis

Year:  2015        PMID: 31763222      PMCID: PMC6848620          DOI: 10.1007/s12070-015-0910-z

Source DB:  PubMed          Journal:  Indian J Otolaryngol Head Neck Surg        ISSN: 2231-3796


  4 in total

Review 1.  Overview of the treatment of allergic rhinitis and nonallergic rhinopathy.

Authors:  Alexander N Greiner; Eli O Meltzer
Journal:  Proc Am Thorac Soc       Date:  2011-03

2.  FDC of montelukast with levocetirizine: focus on bilayer technology.

Authors:  R T Rathod; D Misra
Journal:  J Indian Med Assoc       Date:  2009-08

3.  Long-term montelukast therapy in moderate to severe COPD--a preliminary observation.

Authors:  Israel Rubinstein; Brijesh Kumar; Christopher Schriever
Journal:  Respir Med       Date:  2004-02       Impact factor: 3.415

4.  Allergic Rhinitis: A neglected disease - A community based assessment among adults in Delhi.

Authors:  B Sinha; R Singla; R Chowdhury
Journal:  J Postgrad Med       Date:  2015 Jul-Sep       Impact factor: 1.476

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.